CUPRIMINE

LOE Approaching

penicillamine

Bausch + Lomb
NDAORALCAPSULE
Approved
Dec 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1

Mechanism of Action

CLINICAL PHARMACOLOGY Penicillamine is a chelating agent recommended for the removal of excess copper in patients with Wilson's disease. From in vitro studies which indicate that one atom of copper combines with two molecules of penicillamine, it would appear that 1 g of penicillamine should be…

Pharmacologic Class:

Antirheumatic Agent

Indications (8)

the treatment of Wilson's diseasecystinuriaactive rheumatoid arthritispregnancy because of its low protein content (see )rheumatoid arthritisrecurrent stone formationCUPRIMINE may be usedCUPRIMINE may be a useful substitute

Clinical Trials (1)

NCT01374282N/ANo Longer Available

Post Marketing Surveillance Study of Cuprimine

Scleroderma
Company
Bausch + Lomb
Bausch + Lomb
NJ - Bridgewater
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers